FGEN FibroGen Inc.

FibroGen to Report Third Quarter 2024 Financial Results

FibroGen to Report Third Quarter 2024 Financial Results

SAN FRANCISCO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce third quarter 2024 financial results on Tuesday, November 12 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.

Conference Call and Webcast

Toll-free: 1-877-300-8521

International investors: 1-412-317-6026

Webcast:

To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call. A replay of the webcast will also be available for a limited time on the “” page under the Investors section on the FibroGen website.

About FibroGen  

FibroGen, Inc. is a biopharmaceutical company focused on accelerating the development of novel therapies at the frontiers of cancer biology. Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. Roxadustat is in clinical development for chemotherapy-induced anemia (CIA) and a Supplemental New Drug Application (sNDA) has been accepted for review by the China Health Authority. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46 is in development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of an associated CD46-targeted PET biomarker, FG-3180. In addition, FibroGen has expanded its research and development portfolio to include two immuno-oncology product candidates for the treatment of solid tumors. For more information, please visit .

For Investor Inquiries:

David DeLucia, CFA

Vice President of Corporate FP&A / Investor Relations



EN
04/11/2024

Underlying

FGENFibroGen Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on FibroGen Inc.

 PRESS RELEASE
Free
FGEN FIBROGEN INC.

FibroGen Announces the Sale of FibroGen China to AstraZeneca for Appro...

FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million  Purchase price represents enterprise value of $85 million plus FibroGen net cash held in China at closing, currently estimated to be approximately $75 millionUpon close, FibroGen will repay its term loan to Morgan Stanley Tactical Value, further simplifying the Company’s capital structure Company’s cash runway extended into 2027 Company to continue to advance its oncology pipeline, with the initiation of the Phase 2 monotherapy trial of FG-3246 in metastatic castration-resistant prostate cancer ...

February 20, 2025 1 EN
 PRESS RELEASE
Free
FGEN FIBROGEN INC.

FibroGen Appoints David DeLucia as Chief Financial Officer

FibroGen Appoints David DeLucia as Chief Financial Officer SAN FRANCISCO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of David DeLucia to Chief Financial Officer (CFO), effective December 16, 2024. The company previously announced that Juan Graham would step down on December 15, 2024. Reporting to Chief Executive Officer Thane Wettig, DeLucia will lead and oversee FibroGen’s global finance organization. He has most recently served as FibroGen’s Vice President, Head of Corporate Financial Planning and Analysis, Investor Relations, and ...

December 16, 2024 1 EN
 PRESS RELEASE
Free
FGEN FIBROGEN INC.

FibroGen Reports Third Quarter 2024 Financial Results

FibroGen Reports Third Quarter 2024 Financial Results Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246, a first-in-class antibody-drug conjugate (ADC) targeting CD46, in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) are expected in 1H 2025Initiation of Phase 2 monotherapy dose optimization study of FG-3246 in mCRPC anticipated in 1Q 2025Third quarter net revenue growth of 15% year over year, driven by strong performance of roxadustat in China, with year over year volume growth of 34% Reiterate full ...

November 12, 2024 1 EN
 PRESS RELEASE
Free
FGEN FIBROGEN INC.

FibroGen to Report Third Quarter 2024 Financial Results

FibroGen to Report Third Quarter 2024 Financial Results SAN FRANCISCO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce third quarter 2024 financial results on Tuesday, November 12 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast Toll-free: 1-877-300-8521International investors: 1-412-317-6026Webcast: To access the call, participants should dial the applicable telephone num...

November 4, 2024 1 EN
 PRESS RELEASE
Free
FGEN FIBROGEN INC.

FibroGen to Present at the H.C. Wainwright 26th Annual Global Investme...

FibroGen to Present at the H.C. Wainwright 26th Annual Global Investment Conference SAN FRANCISCO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending and presenting at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 in New York, NY. Thane Wettig, Chief Executive Officer of FibroGen, will deliver a company presentation on Tuesday, September 10 at 3:00 PM ET at the Lotte New York Palace Hotel. A live webcast of the presentation will be available . FibroGen’s management team wi...

September 3, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch